Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy

Seyed-Ali Hosseinian1,2*, Aliakbar Haddad-Mashadrizeh3, Samaneh Dolatabadi1,2

1 Department of Biology, Khorasan Razavi Science and Research Branch, Islamic Azad University, Neyshabur, Iran.
2 Department of Biology, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran.
3 Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, and Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.

Abstract

Purpose: Epithelial cell adhesion molecule (EpCAM) is a dominant antigen in human colon carcinoma tissue. Topology features of this antigen are different in normal and malignant conditions; for instance, EpCAM is much less accessible to antibodies in normal cells than in cancerous tissues. Hence, EpCAM has been considered as a suitable candidate for cancer target therapy via immunotoxins (ITs) development. In this study, attention was focused on the stability assessment of anti-EpCAM-IT (anti-Ep-IT) to design a novel IT.

Methods: The 3D structures of the antibody template and the toxin segment of anti-Ep-IT were retrieved from PDB. Discovery Studio3.0 was used to separate the ligands and water molecules. The antibody (Ab) fragment of anti-Ep-IT was aligned using protein blast (BLAST-p), and SWISS-MODEL database was used for Ab modeling. IT modeling was accomplished using MODELLER 9.15. Also, GROMACS 5.0.7 was used for molecular dynamic (MD) simulation step. Moreover, ERRAT and RAMPAGE databases were used for quality assessment of the structures.

Results: BLAST-p results indicated that antibody moiety of IT has the highest E-value and query coverage scores to the monoclonal antibody (mAb) 4D5MOC-B. Modeling by SWISS-MODEL provided a reasonable template for Ab portion compared to MODELLER. The best modeled full-length IT with the lowest RMSD values was selected. Finally, RMSD plot for MD stage demonstrated constant values from 7000ps to 20000ps.

Conclusion: In general, both modeling results and their quality evaluations were satisfactory for designing IT. Moreover, RMSD plot revealed that IT stability was preserved during the simulation. Overall, our findings led to modeling and simulation of the anti-Ep-IT with more structural stability.

Introduction

Originally discovered in 1979, epithelial cell–adhesion molecule (EpCAM, CD326), type I, transmembrane, 39–42 kDa glycoprotein, was first described as a dominant antigen in human colon carcinoma.1 EpCAM is frequently expressed in human epithelial tumors, mainly in adenocarcinomas and other carcinomas, and it is also stably expressed and even upregulated during the progression of cancer.2 The role of EpCAM is not limited to cell adhesion; it is also involved in cellular signaling, cell migration, proliferation, and differentiation.3,4 EpCAM can be used as a prognostic marker. In certain types of tumors, EpCAM is associated with advance stage disease and overall survival.5 The association of EpCAM with proliferation, adhesiveness, tissue stabilization, promotion of tumor growth, and metastasis suggests that EpCAM is a pleiotropic molecule that potentially offers therapeutic applications in cancer treatment.6 Generally, the expression of EpCAM is restricted to epithelia. More specifically, EpCAM is detected in the basolateral cell membrane of normal human tissue.7 Moreover, EpCAM is believed to be an early marker for (pre)malignancies.8 Enhanced EpCAM expression was found in preneoplastic epithelial of the colon. In colorectal, pancreas, bladder, prostate, breast, and ovarian carcinoma. EpCAM was more intensely positive in tumor cells than in the corresponding normal tissues.9 Ep-CAM-specific antibodies have been used to image and detect primary tumors and metastases in patients with small cell lung cancer and non-small cell lung cancer. Among anti-EpCAM MAbs, PANOREX®, which is a murine monoclonal antibody, also known as edrecolomab, has been approved to be used in the treatment of colon cancer in Germany.10,11 PANOREX® treatment has been associated with undesirable side effects, including abdominal cramps, nausea, transient diarrhea, and

*Corresponding author: Seyed-Ali Hosseinian, Tel: +98 51 42621901-10, Email: a.hoseinian@iau-neyshabur.ac.ir
©2018 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
cutaneous urticarial lesions. However, the search for an effective, low-toxicity, anti-Ep-CAM antibody continues. A humanized, stabilized, single-chain, anti-Ep-CAM antibody, 4D5MOC-B, which is derived from murine monoclonal antibody MOC31, has also been developed. Immunotoxins (ITs) are therapeutic agents with a high degree of specificity and unique mechanism of action. An immunotoxin is a chimeric protein that consists of a targeting moiety linked to a toxin. The targeting moiety selectively binds to a tumor cell and targets it for death via the attached toxin. Generally, immunotoxins are specifically potent against cancer. However, immunotoxins can be limited clinically by immunogenicity, toxicity, and instability. With the advance of recombinant DNA technology, the second-generation ITs are entirely recombinant in the sense that the gene for the Fab or Fv fragments of an antibody is fused with the gene encoding a truncated toxin, followed by transfecting the plasmid vector expressing the recombinant IT into bacteria or yeast for single-chain fusion protein production.

The Fv fragment of an antibody is a heterodimer consisting of heavy-chain (VH) and light-chain (VL) domains and is the smallest functional module retaining the full antigen-binding specificity. To enhance the efficacy of these recombinant immunotoxins (RITs) in treating malignant tumors, great effort has been devoted to reduce the RITs size, identify better antigen targets, improve RIT binding affinity and stability, and prolong retention in the circulation. The centrally located domain II is small and includes residues 253-364 and is composed of 6 alpha helices. In the linear amino acid sequence, domain II separates domain I into 2 subdomains: (1) domain la (aa 1-252) and (2) Ib (aa 365-404). The crystalline structure reveals that 3 of the disulfide bonds of ETA are within domain I and the fourth is in domain II. Domain III, the enzymatic domain encompassing the carboxy-terminal residues 405-613, exhibits a less regular secondary structure than the other 2 domains. An interesting feature of the model proposed for ETA is an extended cleft in domain III, and the active site of the enzyme is within this cleft.

Materials and Methods
To use the toxin subunit in full-length immunotoxin modeling, the crystal structure of the wild-type of Pseudomonas aeruginosa exotoxin A (ETA) (with PDB ID: 1IKQ and 1.62 Å resolution), as the initial structure for the modeling and simulations procedures, was taken from the Protein Data Bank (PDB). To eliminate useless moiety of ETA and the lipid and water molecules from native structures, Discovery Studio Client 3.0 was used; then, new structures were saved again as pdb format. The protein sequence of anti-Ep-IT was obtained from online Google patents. In the next stage, fasta format file of antibody (Ab) moiety was generated. Ab sequence was aligned using BLAST-p program. Subsequently, pattern Ab subunit was retrieved from PDB (with PDB ID: 3AUV and 2.4 Å resolution). MODELLER9.15 software and SWISS-MODEL online program were used to model Ab subunit. Full-length IT was generated by MODELLER 9.15 with multiple align command file. The energy minimization of the globular structure of IT was accomplished with MOE program. The MD simulation was performed by GROMACS 5.07 software with a GROMOS96 43a1 force field. The well-tested SPCE model was used for water molecules, and water molecules in the crystal were reserved during the simulation. The protein was solvated in a cubic box, and the box size was chosen by the following criterion: the distance of protein atoms from the wall had to be greater than 1 nm. The system equilibration was performed gradually at 313 K for 100ps of simulation time in an NVT ensemble and 100ps simulation at 313 K for data sampling in an NPT ensemble. The last step of simulation was MD run at 313 K for 20000ps (20ns) of simulation time. Visualizing the secondary structures of modeled and simulated proteins were accomplished via Pymol. Finally, the output files of MD stage were used for generation of momentary, average pdb files, and RMSD data file. In addition, to draw RMSD plot, Excel was used. Eventually, responsible online programs exhibited Ramachandran and ERRAT plots.

Results
Identifying IT components
To explore structural and functional regions, the protein sequence of IT was investigated. The nucleotide and polypeptide sequences can be divided into the following domains: the signal sequence for periplasmic expression; histidine tags; Ab complementarity-determining regions (CDR) 1, 2, and 3 domains; VH domain; VL domain; linkers; ETA domains II, Ib, III; and an endoplasmic reticulum (ER) retention signal KDE. Ab fragment is made of the single-chain variable fragment of the monoclonal antibody (mAb) 4D5MOC-B, which is a humanized single-chain variable-fragment (scFv) MOC31 antibody and is composed of VH and VL chains. The toxin portion consists of 252 to 608 amino acids (aa) of native ETA. The centrally located domain II is small and includes residues 253-364 and is composed of 6 alpha helices. In the linear amino acid sequence, domain II separates domain I into 2 subdomains: (1) domain la (aa 1-252) and (2) Ib (aa 365-404). The crystalline structure reveals that 3 of the disulfide bonds of ETA are within domain I and the fourth is in domain II. Domain III, the enzymatic domain encompassing the carboxy-terminal residues 405-613, exhibits a less regular secondary structure than the other 2 domains. An interesting feature of the model proposed for ETA is an extended cleft in domain III, and the active site of the enzyme is within this cleft.

Modeling IT components
For full-length IT assemble, at first, it is necessary to build Ab and toxin models and save them as pdb format as major input files. In this regard, crystallography structure of ETA was obtained and then the IA domain of ETA was eliminated from the whole toxin structure to gain toxin model. For model Ab structure outset, Ab was aligned using BLAST-p. The results revealed that a single chain disulfide-stabilized antibody variable fragment (sc-dsFv), derived from the G6-Fab (with PDB ID: 3AUV), had the most similarity to the query sequence (4D5MOC-B mAb). This mAb (G6) consists of 6 chains, and residues of chain A (3AUV_A) has the most sequence coverage to 4D5MOC-B mAb in the region of 1-252. The BLAST scores were as follow: E-
value = 9e-106, query coverage = 99%, and max identity = 66%. Thus, 3AUV_A pdb file was used as the template structure for Ab modeling. Subsequently, the display of secondary structures using Pymol software indicated that in the model developed by the MODELLER software, the VL-VH linker (in the position of 142-165 amino acids) changed to beta structure and 27 N-terminal region amino acids changed to coil, and thus it did not conform to the usual conventional observation of antibodies. Accordingly, modeling Ab moiety again was performed via SWISS-MODEL. In the obtained model, V\textsubscript{L}-V\textsubscript{H} linker sequence was located within the coil protein construction and both Ab chains (V\textsubscript{L} and V\textsubscript{H}) were also displayed as globular structures (normal secondary structures).

Modeling full-length IT
First, the template and input files for modeling based on protein sequences of Ab and ETA subunits were defined. The arrangement of all IT subunits was in “align” file and was exactly compatible with protein sequence of the whole IT. At the end (modeling), among the 10 possible structures, the best structure was selected qualitatively. For the initial verification of IT modeling, the favored structure was compared with the reported pattern in the reference patent document.

Molecular simulation of IT
With the aim of stability evaluation of protein construction of modeled IT in an explicit water solvent environment, MD simulation was used throughout GROMACS. To assess conformational stability rate during the simulation, RMSD of the Ca carbon for overall IT structure in the physiological condition of the body (including pH = 7, temperature = 37°C or 313°K and aqueous solution) was computed. As shown in Figure 1, RMSD values had an increasing trend, ranging from 0ps to 7000ps, and then they remained roughly constant to the end of the simulation (20000ps). In other words, from 7000ps to 20000ps, RMSD values fluctuate between about 1.53Å to 1.72Å. Hence, the instantaneous configuration of the structure was created for these 3 times (0ps, 7000ps, and 20000ps). To evaluate stability in the obtained conformations, changes in secondary structures were scrupulously compared together.

![Figure 1. RMSD of the Ca atoms of overall conformation of simulated IT in 20000ps of simulation time](image)

Assessment of Conformational changes
The visualization of conformations in the aforementioned times specifically indicated that at the beginning of the simulation procedure (Figure 2a), compared with the start point of equilibrium (7000ps) (Figure 2b), some conformations had high fluctuation of basic state or they even shifted to other forms of secondary structures. At first glance, of these undulations, the highest fluctuations were associated with special coil conformations, with having 1 free terminal (such as initial OmpA signal peptide and terminal ER retention signal peptide) as well as long sequence coils (such as V\textsubscript{L}-V\textsubscript{H} linker and Ab-ETA linker). As expected, structures that did not have a secondary structural pattern (such as the His-tag motif) changed to coil. Moreover, as demonstrated in Figure 2a, 3 cores of fluctuation have been distinguished in overall conformation in the initial moment, which are as follow: (1) the initial part of the subunit antibody chain (including beta 1, 2, 3, 8, 10, and alpha 1 spirals) adjacent to the VL-VH linker; (2) some parts of the dermal II (including alpha 10, 11, 16) and dominant Ib (including Helix 3.10 18) exotoxin A; (3) Dimension 3 (including Alpha 20, 23, 27, 28) exotoxin A. In addition, some shifting was distinctive in particular spaces, such as beta strand 11 of Ab in VH domain.
Further, more exploration of shifting conformation in 7000ps moment, compared with the end point of MD simulation (20000ps) (Figure 2b), revealed that although overall conformation progressed toward more stability, some of the above-mentioned regions (such as beta strand 11 in Ab moiety and alpha helixes 20, 28) still had some fluctuations. Also, there were new regions that shifted to other conformations. These points comprised of beta strands 13 and 21 in Ab section and beta strand 23 and turn 29 in ETA section, all of which having shifted to the coil conformation (Figure 2b). At the end of the procedure (20000ps) (Figure 2c), overall conformation of IT took a globular form (general form of the secondary structure of protein). Also, both subtypes of antibodies and exotoxin A were aligned. On the other hand, the regions that did not have any reasonable pattern for their secondary structures, such as initial and terminal signal peptides and linkers, were more folded and thus assumed more stability (Figure 2c).

**Figure 2.** Shifting conformational stability of IT secondary structures in (a) 0ps, (b) 7000ps and (c) 20000ps of simulation time

### Conformations alignment

To verify the conformational authenticity of the final simulated IT, alignment of Ab and ETA fragments to the templates conformations was accomplished. The achieved results for the alignment of Ab subunit of simulated IT to template Ab, with PDB ID: 3AUV-A (Figure 3a), clearly led to identifying 8 distinguished refolded regions compared with crystallography structure of Ab template.
Of these conformation changes, 2 coil to turn shifting occurred, one segment in Ile163, Ser164, Asp165 residues (Figure 3a-1), and another in Ala254, Glu255, Asp256 residues (Figure 3a-2), respectively. The one coil to turn shifting was situated in Asp228, Ser229, and Phe230 residues (Figure 3a-2). In addition, 4 coil to beta change occurred, with one in Thr130, Phe131, and Gly132 residues (Figure 3a-3) and 3 others in Ser39, Ala40, Ser41, Asp45, Arg46, Val47 residues, and Glu138, Leu139, and Lys140 residues (Figure 3a-4), respectively. Eventually, the final conformational change corresponded to V₁-V₅ linker motif of Ab part of IT. In fact, this section was not in Ab template. As demonstrated in Figure 3a-5, because of lack of templates for linker secondary structure, coil conformation may be more appropriate. On the other hand, in the alignment of ETA subunit of IT to the equivalent crystallography structure of ETA with PDB ID (1KQ; Figure 3b), there were 4 regions with different configurations plus a change of direction compared to the original natural structure. Among these 4 accurate conformational shifting, there were 3 coil to helix shifting in the locations of Thr324, Arg325, and His326 residues (Figure 3b-1), Pro626, Arg627, Asn628 residues (Figure 3b-3), and Phe451 and Leu452 residues (Figure 3b-4). Moreover, 1 helix to coil shifting occurred in Ala434, Asp435, and Ser436 residues (Figure 3b-5). Furthermore, a direction shifting occurred at the loop conformation in the location of Glu537, Pro538, Asp539, Ala540, Arg541, Gly542, Arg543, Ile544, and Arg545 residues (Figure 3b-2) in the overall IT sequence.

Figure 3. Alignment of Ab (a) and ETA (b) fragment for simulated IT
Structure quality assessment

To evaluate the quality of modeled Ab (4D5MOC-B) alone, and overall modeled and simulated ITs, Ramachandran plots were created, which showed the distribution of $\varphi$ and $\psi$ angles in the modeled and simulated models. In association with Ramachandran plot of Ab part alone, of 252 residues existing in sequence, 88.5% of residues (223 aa) were located in the most favored region, 9.1% (23 aa) in the allowed region, and only 2.4% (6 aa) in the outlier region (data not shown). In addition, plots were created for both modeled and simulated conformations of IT. According to the plot statistics, as shown in Figure 4a, of the total number of 669 residues of overall IT sequence, 96.3% of residues (644 aa) were located in the most favored region, 2.5% (17 aa) in the allowed region, and only 1.2% (8 aa) in the outlier region, despite intensity of residues number. As displayed in Figure 4b, the 8t residues that were located in the outlier region comprised of Gln18, Ser56, Met84, Thr143, Ser145, Gln150, Ala154, and Ser282 residues. Among these residues, Gln18 was in the position of OmpA initial signal and Ser56 and Met84 were in $\text{V}_L$ chain of Ab fragment. Furthermore, Thr143, Ser145, Gln150, and Ala154 residues were located in $\text{V}_L$-$\text{V}_H$ linker, and Ser282 in $\text{V}_H$ domain. The quality protein structure was verified with ERRAT, where ERRAT plot showed overall quality factor 79.668 for 4D5MOC-B. These values for the completely modeled and simulated ITs were 62.323 and 80.514, respectively (data not shown).

Discussion

Functional characterization of a protein sequence is one of the most frequent problems in biology. In the absence of an experimentally determined structure comparative or homology modeling can provide a useful 3D model for a protein (target) that is related to at least one known protein structure (template). 28-30 Even models with errors may be useful because some aspects of the function can
be predicted only from coarse structural features of a model.\textsuperscript{30} In the first stage of this study, the alignment of the query Ab (4D5MOC-B) to template Ab (3AUV-A) represented 99% query coverage and 66% identity value. Modeling structures in all patterns associated with models, based on 50% sequence matching or more, generally have no errors.\textsuperscript{31} Models with such high accuracy have been shown to be useful even for refining crystallographic structures by molecular replacement method.\textsuperscript{32} Nevertheless, the resulting conformation of MODELLER program, due to unfolding N-terminal region of Ab V\textsubscript{L} domain as well as beta folding V\textsubscript{L}-V\textsubscript{H} linker instead of the common coil form, was ineligible. Therefore, in the modeling process, we used SWISS-MODEL that led to creating the compatible model with known Ab conformations for crystallography structures (template). Ramachandran plot criteria for backbone conformation emphasize on distinguishing the rare from erroneous \(\phi, \psi\) values, touched briefly on sidechain criteria. Ideal bond angle values are known through highly accurate small molecule structures\textsuperscript{35} and traditional structure validation reports\textsuperscript{36,37} flag outliers that deviate by more than a few standard deviations. A residue with the good fit to favored \(\phi, \psi\) values, no atomic clashes, and ideal covalent geometry is almost certainly modeled correctly.\textsuperscript{32} Thus, among 10 modeled conformations via MODELLER in both Ramachandran and ERRAT criteria, the best model with almost 98.8% of residues located in appropriate position, ERRAT score 62.323, is preferred. The obtained structure of overall IT simulation in physiologic conditions (313°K, pH = 7) showed that the ERRAT overall quality factor increased to 80.514, representing more stable conformation during the simulation procedure. Moreover, it is deduced from the RMSD chart that after only 7000ps of simulation time due to reaching (RMSD values) to a constant mean value of about 1.6 Å, the configuration was further improved to a greater stability. Comparison of RMSD and conformations results at specified intervals revealed that the initial high fluctuation of RMSD value in the initial moment of simulation caused instability of special sections of MD simulated IT. These regions comprised of conformation without pattern motifs, such as signal peptides and linkers as well as some secondary structures containing most of the beta sheets of Ab V\textsubscript{L} chain together with several regions of alpha helices form of II, Ib, and III domains of ETA. Corresponding to 7000ps momentary conformation, there were fewer fluctuating and refolding regions, including 3 beta strands in V\textsubscript{H} chain of Ab and 2 alpha helices, 1 beta strand, and 1 turn folding, which were completely located in the catalytic domain of ETA (domain III). Then, the structure fluctuations were reduced in the interval from 7000ps to 20000ps because of the stability of the RMSD values. Overall, at the end of the simulation (20000ps), the comprehensive structure of IT was directed to folded conformations for both Ab and ETA moieties. To confirm the authentication of MD simulation, Ab and ETA subunits of the average simulated IT conformation were aligned with native and template structures. In this regard, the Ab alignment exhibited 8 refolding (7 refolded regions+1 excess V\textsubscript{L}-V\textsubscript{H} linker) that included 4 coil→beta, 1 coil→turn, 2 turn→coil, and 1 linker in the form of coil. Considering that beta and turn folding had more stability compared to coil folding, because of interchain hydrogen bonds, 5 of 8 refolding (4 coil→beta+1 coil→turn) led to creating more stable conformation. Generally, the folding linker VL-VH should be in the form of coil. The most important challenge of the mentioned IT simulation was placing 2 remaining refolded parts (turn→coil) in 240-242 and 254-256 regions of IT sequence. As these regions were precisely located in the position of antigen binding site of V\textsubscript{H} chain of Ab (paratope areas), they could interfere with Ab-antigen binding procedure. In addition, the turn-to-coil transformation is a source of instability in the immunotoxin conformation due to the reduction in the number of hydrogen bonding in the globular structure, so it could partly cause instability of simulated conformation. ETA fragment of overall IT and its native 3D structure were aligned in the last stage of conformational comparison. The results revealed that despite using the crystallographic structure of ETA with PDB ID (1IKQ as toxin moiety template of IT in energy minimization step of MD simulation), ETA structure developed to more stable and refolded conformation. In this regard, 4 refolded regions of 5 prominent refolding have progressed into the more established configuration that contained 3 coil→helix refold plus a loop folding of 538-545 residues of comprehensive IT. It seems that changes occurred due to elimination of Ia domain from the native structure and the combination of unfolded motifs of Ab-ETA linker and ER retention signal peptide to N- and C-terminal domains of ETA. It is considered that of 5 rearrangements of ETA fraction, 1 territory was correlated to domain II, 2 to domain Ib, and 2 others corresponded to domain III or catalytic domain of ETA. Finally, the overall outcomes of the quality assessment based on Ramachandran plot and ERRAT characterization revealed a higher quality of simulated IT conformation, with 98.8% residues located in the authorized area and 80.514 for overall quality factor, compared to early modeled IT and Ab fragment alone.

**Conclusion**

Recent advances in antibody engineering have provided a number of functionally optimized anti-EpCAM antibodies.\textsuperscript{38} Anti-EpCAM antibody conjugated with alpha-amanitin has the potential to be a highly effective therapeutic agent for pancreatic carcinoma and various EpCAM-expressing malignancies.\textsuperscript{39} Since 1970s, the method of MD simulation has gained popularity in biochemistry and biophysics.\textsuperscript{40} The aim of this study was to offer a reasonable pattern of anti-EpCAM IT model to design the novel generation of recombinant IT. Determining stability of IT and identifying unstable regions can lead us to increase efficiency and sustainability of anticancer drugs in physiologic...
conditions. Overall, our findings led to validation of the simulated stability model for intended IT in most areas.

Acknowledgments
Authors are thankful to the Islamic Azad University of Neyshabur and gratefully acknowledge Khayyam bioeconomic company of Mashhad for allowing to use all computational facilities.

Ethical Issues
Not applicable.

Conflict of Interest
The authors declare no conflict of interests.

References
1. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigens: Detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A 1979;76(3):1438-42. doi: 10.1073/pnas.76.3.1438
2. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev 2012;38(1):68-75. doi: 10.1016/j.ctrv.2011.04.002
3. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am J Pathol 2007;171(2):386-95. doi: 10.2353/ajpath.2007.070152
4. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11(2):162-71. doi: 10.1038/ncb1824
5. Oladi F, Yossefi E, Momeni-Moghadam M. The role of EpCAM in cancer progression. Journal of Cellular Immunotherapy 2017;3(1):10. doi: 10.1016/j.joic.2017.04.014
6. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64(16):5818-24. doi: 10.1158/0008-5472.CAN-04-0754
7. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999;77(10):699-712. doi: 10.1007/s001099900038
8. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, Van Krieken H, Fleuren GI, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996;148(3):865-75
9. Winter MJ, Nagtegaal ID, van Krieken JHJ, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003;163(6):2139-48. doi: 10.1016/S0002-9440(10)63570-5
10. Schwartzberg LS. Clinical experience with edrecolomab: A monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001;40(1):17-24. doi: 10.1016/S1040-8428(01)00131-7
11. Adkins JC, Spencer CM. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998;56(4):619-26. doi: 10.2165/00003495-19985604-00011
12. Haller DG. Update of clinical trials with edrecolomab: A monoclonal antibody therapy for colorectal cancer. Semin Oncol 2001;28(1 Suppl 1):25-30.
13. Hartung G, Franz A, Sturm J, Edler L, Bornbush D, Gonnermann M, et al. Prospective randomized study of adjuvant therapy with edrecolomab (panorex®) of stage II colon cancer: Interim analysis. Ann Oncol 2000;11:47.
14. Sizmam N, Korting HC. Prolonged urticaria with 17-1A antibody. BMJ 1998;317(7173):1631. doi: 10.1136/bmj.317.7173.1631
15. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002;100(1):101-10. doi: 10.1002/ijc.10443
16. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59(22):5758-67.
17. Pennell CA, Erickson HA. Designing immunotoxins for cancer therapy. Immunol Res 2002;25(2):177-91. doi: 10.1385/ir:25:2:177
18. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11(4):1545-50. doi: 10.1158/1078-0432.CCR-04-1939
19. Brinkmann U, Pastan I. Recombinant immunotoxins: From basic research to cancer therapy. Methods 1999;8(2):143-56. doi: 10.1006/meth.1999.9992
20. Chen KC, Kim J, Li X, Lee B. Modeling recombinant immunotoxin efficacies in solid tumors. Ann Biomed Eng 2008;36(3):486-512. doi: 10.1007/s10439-007-9425-4
21. Benhar I, Pastan I. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J Biol Chem 1995;270(40):23373-80. doi: 10.1074/jbc.270.40.23373
22. Bera TK, Onda M, Brinkmann U, Pastan I. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. J Mol Biol 1998;281(3):475-83. doi: 10.1006/jmbi.1998.1948
23. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, et al. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human
breast cancer cells in vitro. *Biochemistry* 1997;36(1):66-75. doi: 10.1021/bi962148u

24. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. *Proc Natl Acad Sci U S A* 2000;97(15):8548-53. doi: 10.1073/pnas.140210597

25. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific animal toxicity of anti-tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. *J Immunol* 1999;163(11):6072-7.

26. Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, et al. Lowering of the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. *Cancer Res* 2001;61(13):5070-7.

27. Hessler JL, Kreitman RJ. An early step in pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. *Biochemistry* 1997;36(47):14577-82. doi: 10.1021/bi971447w

28. Browne WJ, North AC, Phillips DC, Brew K, Vanaman TC, Hill RL. A possible three-dimensional structure of bovine a-lactalbumin based on that of hen's egg-white lysozyme. *J Mol Biol* 1969;42(1):65-86. doi: 10.1016/0022-2836(69)90487-2

29. Becker OM, MacKerell Jr AD, Roux B, Watanabe M. Computational biochemistry and biophysics. CRC Press; 2001.

30. Fiser A, Šali A. Modeller: Generation and refinement of homology-based protein structure models. *Methods Enzymol* 2003;374:461-91. doi: 10.1016/S0076-6879(03)74020-8

31. Sanchez R, Sali A. Evaluation of comparative protein structure modeling by modeller-3. *Proteins* 1997;29(S1):50-8.

32. Howell PL, Almo SC, Parsons MR, Hajdu J, Petsko GA. Structure determination of turkey egg-white lysozyme using laue diffraction data. *Acta Crystallogr B* 1992;48(2):200-7. doi: 10.1107/S0108768191012466

33. Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. *Proteins* 2003;50(3):437-50. doi: 10.1002/prot.10286

34. Lovell SC, Word JM, Richardson JS, Richardson DC. The penultimate rotamer library. *Proteins* 2000;40(3):389-408.

35. Engh RA, Huber R. Accurate bond and angle parameters for X-ray protein structure refinement. *Acta Crystallogr Sect A: Found Crystallogr* 1991;47(4):392-400. doi: 10.1107/S0108767391001071

36. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. Procheck: A program to check the stereochemical quality of protein structures. *J Appl Crystallogr* 1993;26(2):283-91. doi: 10.1107/S0021889892009944

37. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. *Nature* 1996;381(6580):272. doi: 10.1038/38127a0

38. Simon M, Stefan N, Plickthun A, Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. *Expert Opin Drug Deliv* 2013;10(4):451-68. doi: 10.1517/17425247.2013.759938

39. Zhu G. EpCAM-an old cancer antigen, turned oncogenic receptor and its targeting immunotherapy. *Univ J Pharm Res* 2018;3(2):43-8. doi: 10.22270/ujpr.v3i2.140

40. McCammon JA, Gelin BR, Karplus M. Dynamics of folded proteins. *Nature* 1977;267(5612):585-90. doi: 10.1038/267585a0